Lupus drug may shield heart and arteries
NCT ID NCT05440422
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in artery stiffness and vessel inflammation using special scans and tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anifrolumab
- What this could lead to
- If it works, this could point toward a way to lower heart attack and stroke risk in people with lupus.
- What could go wrong
- This is a small, early-phase trial with only 45 participants, so results may not apply to everyone. The drug may not improve blood vessel health or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- Can a single infusion tame tough lupus?
- Virtual fitness for aging hearts: a new frontier in cardiac rehab?
- Could a simple annual blood test shield cancer survivors from heart attacks and strokes?